One victory for biopharma over the coronavirus in 2020
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Astrazeneca shows megamergers were still possible in 2020
One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Hope versus experience in glioblastoma
Development of new drugs for this hard-to-treat brain cancer is a slow and incremental process.
Go or no go? New Year approval decisions for the US regulators
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
Who will follow Curis’s clinical validation?
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
Uniqure’s safety scare shakes haemophilia gene therapy
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.
